{"id":7742,"date":"2015-10-01T18:21:17","date_gmt":"2015-10-01T22:21:17","guid":{"rendered":"http:\/\/blogs.nejm.org\/hiv-id-observations\/?p=7742"},"modified":"2015-10-01T22:37:05","modified_gmt":"2015-10-02T02:37:05","slug":"who-decision-to-recommend-treatment-for-all-with-hiv-an-easy-one-now-comes-the-hard-part","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/who-decision-to-recommend-treatment-for-all-with-hiv-an-easy-one-now-comes-the-hard-part\/2015\/10\/01\/","title":{"rendered":"WHO Decision to Recommend Treatment for All with HIV an Easy One &#8212; Now Comes the Hard Part"},"content":{"rendered":"<p>In the newspaper today &#8212; and yes, we still do get it delivered (some habits die hard) &#8212; is <a href=\"http:\/\/www.nytimes.com\/2015\/10\/01\/health\/millions-more-need-hiv-treatment-who-says.html?ref=health\" target=\"_blank\">this headline<\/a>:<\/p>\n<p style=\"padding-left: 30px;text-align: center\"><strong>Millions More Need H.I.V. Treatment, W.H.O. Says<\/strong><\/p>\n<p>It&#8217;s true &#8212; these <a href=\"http:\/\/www.who.int\/mediacentre\/news\/releases\/2015\/hiv-treat-all-recommendation\/en\/\" target=\"_blank\">updated guidelines<\/a> say that all should be treated soon after\u00a0diagnosis, regardless of CD4 cell count or whether they have symptoms.<\/p>\n<p>Now, a certain <a href=\"http:\/\/hydeparkpedi.com\/about-us\/physicians\/\" target=\"_blank\">non-ID doctor<\/a> read the headline this morning, and asked me what the big deal is. After all, she&#8217;s been hearing about our treating everyone with HIV here for years &#8212;\u00a0<a href=\"https:\/\/aidsinfo.nih.gov\/contentfiles\/AdultandAdolescentGL003093.pdf\" target=\"_blank\">since 2012<\/a>, if you want to be precise about it.<\/p>\n<p>Even before that, in trendy San Francisco, the Department of Public Health <a href=\"http:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/san-francisco-public-health-hiv-treatment-recommended-for-all\/2010\/04\/04\/\" target=\"_blank\">in 2010 recommended\u00a0treatment for all people with HIV<\/a> regardless of CD4 cell count.\u00a0Today\u00a0this decision is paying big dividends in that city, with a decline in new HIV diagnoses probably linked to this policy in action.<\/p>\n<p>Indeed, given the results of the START, TEMPRANO, and HPTN 052 studies, the WHO&#8217;s decision to modify its recommendation is about as surprising as Jerry&#8217;s telling George, Kramer, and Elaine that he wants to have lunch at <a href=\"https:\/\/en.wikipedia.org\/wiki\/Monk%27s_Caf%C3%A9\" target=\"_blank\">Monk&#8217;s.<\/a><\/p>\n<p>(Not sure why I thought of that analogy. Must be hungry.)<\/p>\n<p>The data are now so overwhelmingly in favor of universal treatment of HIV infection\u00a0that I can only think of one subset of patients for whom therapy has not been <em>proven<\/em>\u00a0to be beneficial. These are the rare &#8220;HIV controllers&#8221; with undetectable virus and normal CD4 cell counts even without treatment.\u00a0My hunch is that it probably benefits them too, though this is still under study.<\/p>\n<p>The challenge, of course, is putting the &#8220;treat-all&#8221;\u00a0policy into action.\u00a0In Sub-Saharan Africa, the UNAIDS estimate of the proportion of people living with HIV who have been diagnosed <em><a href=\"http:\/\/www.natap.org\/2015\/IAS\/Jake_IAS_Slides_July20X.pdf\">is only 51%.<\/a><\/em> Obviously, the other 49% are not getting any sort of treatment unless there is\u00a0a massive HIV testing campaign.<\/p>\n<p>In addition, treatment of everyone will likely strain both human resources and medication supply, with\u00a0an additional 9 million people eligible for treatment but no new funding source to pay for it. As such, there&#8217;s an important statement <a href=\"http:\/\/apps.who.int\/iris\/bitstream\/10665\/186275\/1\/9789241509565_eng.pdf?ua=1\" target=\"_blank\">in the guidelines<\/a> about whom to treat if resources are limited:<\/p>\n<blockquote><p>Regardless of the epidemic profile and disease burden, priority should be given to people with symptomatic HIV disease or with CD4 count at or below 350 cells\/mm3 who are at high risk of mortality and most likely to benefit from ART in the short term.<\/p><\/blockquote>\n<p>In other words, if you can&#8217;t treat everyone, treat the sickest first &#8212; they have much more to gain survival-wise than healthier people with HIV, so you definitely get more for your human and pharmaceutical investment.<\/p>\n<p>But are clinical\u00a0programs set up to do this? I suspect that with this recent WHO Guidelines change, most\u00a0will operate under a\u00a0&#8220;first-come, first-served&#8221; approach, offering treatment to everyone that shows up &#8212; until medication supplies run out or the clinic gets overwhelmed. As my colleague Ben Linas noted years ago when studying <a href=\"http:\/\/cid.oxfordjournals.org\/content\/43\/10\/1357.long\" target=\"_blank\">AIDS Drug Assistance Program waiting lists<\/a>, this is not the best approach to maximize impact with\u00a0limited resources.<\/p>\n<p>The change in the WHO Guidelines, unsurprising as it might be, makes good sense scientifically. Time for a different sort of science &#8212; &#8220;implementation science&#8221; &#8212; to figure out how to make it happen, and how to benefit people the most.<\/p>\n<p>Back to Monk&#8217;s.<\/p>\n<p>[youtube http:\/\/www.youtube.com\/watch?v=8LafoDMH6Tw&amp;w=420&amp;h=315]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In the newspaper today &#8212; and yes, we still do get it delivered (some habits die hard) &#8212; is this headline: Millions More Need H.I.V. Treatment, W.H.O. Says It&#8217;s true &#8212; these updated guidelines say that all should be treated soon after\u00a0diagnosis, regardless of CD4 cell count or whether they have symptoms. Now, a certain [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-7742","post","type-post","status-publish","format-standard","hentry","category-health-care"],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts\/7742","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/comments?post=7742"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts\/7742\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/media?parent=7742"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/categories?post=7742"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/tags?post=7742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}